Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BVS

Bioventus Inc

Mar 21 • 04:00PM ET

9.65

Dollar change -0.09
Percentage change -0.92	%

Healthcare • Medical Devices • USA • NASD

Peers: ZBH SNN GMED IART XRAY OFIX BAX CNMD PODD MEDP

| Held by: VTI IWM AVUV VXF IWN FESM SCHA VTWO VHT XHE

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.52	Insider Own	31.68%	Shs Outstand	65.76M	Perf Week	0.42%
Market Cap	790.76M	Forward P/E	11.35	EPS next Y	0.85	Insider Trans	-0.25%	Shs Float	45.20M	Perf Month	-3.02%
Income	-33.54M	PEG	-	EPS next Q	0.02	Inst Own	49.30%	Short Float	1.76%	Perf Quarter	-13.45%
Sales	573.28M	P/S	1.38	EPS this Y	34.01%	Inst Trans	1.73%	Short Ratio	2.46	Perf Half Y	-17.45%
Book/sh	2.25	P/B	4.29	EPS next Y	29.44%	ROA	-4.36%	Short Interest	0.79M	Perf Year	78.70%
Cash/sh	0.51	P/C	19.02	EPS next 5Y	16.76%	ROE	-20.86%	52W Range	3.90 - 14.38	Perf YTD	-8.10%
Dividend Est.	-	P/FCF	21.60	EPS past 5Y	-113.92%	ROI	-7.10%	52W High	-32.89%	Beta	0.88
Dividend TTM	-	Quick Ratio	0.87	Sales past 5Y	11.88%	Gross Margin	66.39%	52W Low	147.44%	ATR (14)	0.57
Dividend Ex-Date	Mar 26, 2004	Current Ratio	1.31	EPS Y/Y TTM	79.18%	Oper. Margin	4.68%	RSI (14)	46.58	Volatility	4.51% 5.56%
Employees	930	Debt/Eq	2.41	Sales Y/Y TTM	11.89%	Profit Margin	-5.85%	Recom	1.67	Target Price	15.00
Option/Short	Yes / Yes	LT Debt/Eq	2.20	EPS Q/Q	97.52%	Payout	-	Rel Volume	1.37	Prev Close	9.74
Sales Surprise	5.84%	EPS Surprise	81.60%	Sales Q/Q	13.45%	Earnings	Mar 11 BMO	Avg Volume	322.12K	Price	9.65
SMA20	-1.98%	SMA50	-4.14%	SMA200	-1.77%	Trades		Volume	441,021	Change	-0.92%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-24	Upgrade	JP Morgan	Underweight → Neutral	$12 → $13
Dec-07-23	Upgrade	Canaccord Genuity	Hold → Buy	$7
Aug-09-23	Upgrade	Craig Hallum	Hold → Buy	$4 → $6
Nov-22-22	Downgrade	Craig Hallum	Buy → Hold
Nov-09-22	Downgrade	JP Morgan	Overweight → Underweight
Nov-09-22	Downgrade	Canaccord Genuity	Buy → Hold	$18 → $6
Mar-15-22	Initiated	Craig Hallum	Buy	$30
Nov-15-21	Resumed	Morgan Stanley	Overweight	$20
Nov-10-21	Resumed	JP Morgan	Overweight	$25
Jul-01-21	Downgrade	Goldman	Buy → Neutral	$20 → $19
Mar-08-21	Initiated	Morgan Stanley	Overweight	$18
Mar-08-21	Initiated	JP Morgan	Overweight	$17
Mar-08-21	Initiated	Goldman	Buy	$19
Mar-08-21	Initiated	Canaccord Genuity	Buy	$23

Show Previous Ratings

Mar-17-25 12:00PM	Bioventus (BVS) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-12-25 03:08AM	Q4 2024 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) -6.76%
03:04AM	Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ... (GuruFocus.com)
Mar-11-25 08:45AM	Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates (Zacks) +23.29%
07:52AM	Bioventus: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Loading…
07:30AM	Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-28-25 07:30AM	Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025 (GlobeNewswire)
Jan-07-25 08:00AM	Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-25 08:05AM	Bioventus completes divestiture of its Advanced Rehabilitation business (TipRanks)
Jan-02-25 08:00AM	Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners (GlobeNewswire)
Dec-23-24 09:40AM	Is Bioventus (BVS) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-06-24 09:55AM	Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet (Zacks)
Nov-06-24 02:43AM	Q3 2024 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents)
02:14AM	Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... (GuruFocus.com)
Nov-05-24 08:45AM	Bioventus (BVS) Matches Q3 Earnings Estimates (Zacks) -16.27%
07:41AM	Loading…
07:41AM	Bioventus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Bioventus Reports Third Quarter Financial Results (GlobeNewswire)
Nov-04-24 09:40AM	Are Medical Stocks Lagging Bioventus (BVS) This Year? (Zacks)
07:09AM	Bioventus Inc (BVS) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-29-24 07:30AM	Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024 (GlobeNewswire)
Oct-15-24 04:01PM	Solventum Stock Earns 81 RS Rating (Investor's Business Daily)
Oct-09-24 05:03PM	Bioventus Inc (BVS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Oct-01-24 09:00AM	Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners (GlobeNewswire)
Aug-29-24 07:09AM	Bull Of The Day: Bioventus (BVS) (Zacks)
Aug-07-24 04:15PM	Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference (GlobeNewswire) -7.79%
Aug-06-24 07:30AM	Bioventus Reports Second Quarter Financial Results (GlobeNewswire) +29.23%
Jul-30-24 07:30AM	Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jun-05-24 10:17AM	Here's Why You Should Consider Buying Bioventus (BVS) Stock (Zacks)
May-23-24 06:42AM	3 Stocks Under $10 With Mammoth Growth Prospects (InvestorPlace)
May-09-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +8.33%
12:28PM	Loading…
May-08-24 12:28PM	Bioventus Inc. (NASDAQ:BVS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:19AM	Bioventus Inc (BVS) Q1 2024 Earnings Call Transcript Highlights: Strong Start with Significant ... (GuruFocus.com)
May-07-24 11:41PM	Q1 2024 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +28.00%
07:00AM	Bioventus Reports First Quarter Financial Results (GlobeNewswire)
Apr-29-24 07:30AM	Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Mar-13-24 08:48AM	Bioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.54%
Mar-12-24 10:20PM	Q4 2023 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +5.46%
09:11AM	Bioventus Inc (BVS) Reports Growth in Q4 Sales and Adjusted EBITDA, Provides Optimistic 2024 ... (GuruFocus.com)
07:30AM	Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-04-24 08:00AM	Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024 (GlobeNewswire)
Jan-18-24 04:15PM	Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility (GlobeNewswire)
Jan-12-24 04:15PM	Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole (GlobeNewswire)
Dec-19-23 04:30PM	Bioventus Names Robert Claypoole as President and Chief Executive Officer (GlobeNewswire)
Dec-06-23 08:00AM	Bioventus Agrees to Nationwide Contract with Aetna Medicare Advantage Plans for DUROLANE for Knee Osteoarthritis (GlobeNewswire)
Nov-27-23 01:33AM	Smith & Nephew inks $180M CartiHeal buyout, capitalizing on Bioventus turmoil to land knee implant (MedTech Dive)
Nov-12-23 09:02AM	Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 07:59AM	Bioventus Inc (BVS) Reports Q3 2023 Financial Results, Raises Full Year 2023 Financial Guidance (GuruFocus.com)
07:00AM	Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance (GlobeNewswire)
Oct-31-23 07:00AM	Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023 (GlobeNewswire) +5.37%
Oct-25-23 10:48AM	Bioventus (BVS) to Report Q3 Earnings: What's in the Cards? (Zacks)
Sep-28-23 07:43AM	3 Value Medical Stocks to Buy for Safety Amid Market Volatility (Zacks)
Sep-19-23 09:52PM	Bioventus to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-23 04:30PM	Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-16-23 09:02AM	Juniper Investment Company, LLC Increases Stake in Bioventus Inc (GuruFocus.com) -5.26%
Aug-10-23 08:09AM	Bioventus works to trim debt under interim CEO (American City Business Journals) +11.74%
Aug-08-23 10:02PM	Q2 2023 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +14.12% +5.41%
07:30AM	Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance (GlobeNewswire)
Aug-04-23 08:30AM	Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference (GlobeNewswire)
Aug-01-23 05:35PM	Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jun-23-23 06:35PM	Madrigal Pharmaceuticals and Bioventus Stock See Action From Activist Investors (Barrons.com) -7.02%
May-25-23 06:38AM	Daily Vickers Top Buyers & Sellers for 05/25/2023 (Argus Research)
May-23-23 07:30AM	Bioventus Completes Divestiture of its Wound Business (GlobeNewswire) +16.27%
May-18-23 12:07PM	Bioventus Inc. (NASDAQ:BVS) Q1 2023 Earnings Call Transcript (Insider Monkey) +11.45%
May-17-23 08:33AM	Q1 2023 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +9.17%
May-16-23 04:15PM	Bioventus Reports First Quarter Financial Results (GlobeNewswire)
May-15-23 05:33PM	Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023 (GlobeNewswire)
May-11-23 07:00AM	Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023 (GlobeNewswire) +17.48%
May-10-23 09:00AM	Bioventus Announces Divestiture of its Wound Business (GlobeNewswire) +6.95%
May-03-23 08:30AM	Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023 (GlobeNewswire)
Apr-08-23 08:55AM	While institutions invested in Bioventus Inc. (NASDAQ:BVS) benefited from last week's 22% gain, private equity firms stood to gain the most (Simply Wall St.)
Apr-05-23 10:52AM	Bioventus Inc. (NASDAQ:BVS) Q4 2022 Earnings Call Transcript (Insider Monkey) +12.73%
08:00AM	Bioventus Announces CEO Leadership Change (GlobeNewswire)
07:38AM	New Strong Sell Stocks for April 5th (Zacks)
Mar-31-23 07:30AM	Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results (GlobeNewswire) -11.57%
07:00AM	Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility (GlobeNewswire)
Mar-30-23 04:51AM	Heres Why Bioventus (BVS) Declined in Q4 (Insider Monkey)
Mar-29-23 08:55AM	Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023 (GlobeNewswire)
Mar-20-23 10:16AM	Are Options Traders Betting on a Big Move in Bioventus (BVS) Stock? (Zacks)
Mar-16-23 08:30AM	Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023 (GlobeNewswire) -12.88%
Feb-28-23 07:30AM	Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition (GlobeNewswire) +45.89%
Jan-27-23 02:49PM	Bioventus to divest assets ahead of major payments coming due (American City Business Journals)
Jan-14-23 03:14PM	15 Largest Orthopedic Companies in the World (Insider Monkey)
Jan-04-23 07:00AM	Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-22 02:53PM	2022 Year in Review: Layoffs hit Triangle biotech, pharma companies (American City Business Journals)
Dec-09-22 11:58AM	Durham's Bioventus slashing headcount to rein in expenses (American City Business Journals)
Nov-28-22 10:34PM	Why this Durham firm's stock is down more than 70% this month (American City Business Journals) -20.41%
Nov-21-22 05:15PM	Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance (GlobeNewswire)
Nov-16-22 05:15PM	Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022 (GlobeNewswire) -9.45% -33.67%
Nov-10-22 05:38AM	Bioventus Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.) +25.58%
Nov-09-22 06:18PM	Why Shares of Bioventus Fell 14% on Wednesday (Motley Fool) -14.00%
Nov-08-22 07:30AM	Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance (GlobeNewswire) -57.51%
Oct-31-22 07:00AM	Bioventus to Report Third Quarter of Fiscal Year 2022 Financial Results on November 8, 2022 (GlobeNewswire)
Oct-12-22 08:00AM	Bioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago (GlobeNewswire)
Aug-30-22 08:00AM	Bioventus to Present at the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-12-22 02:32AM	Bioventus Inc. (BVS) Q2 2022 Earnings Call Transcript (Motley Fool) +7.84%
Aug-11-22 07:00AM	Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance (GlobeNewswire)
Aug-03-22 07:00AM	Bioventus Receives FDA 510(k) Clearance for SonaStar Elite (GlobeNewswire)
Jul-26-22 07:00AM	Bioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022 (GlobeNewswire)
Jul-12-22 08:30AM	Bioventus Completes CartiHeal Acquisition (GlobeNewswire) +9.67%
Jul-04-22 10:00AM	Investors one-year losses grow to 57% as the stock sheds US$66m this past week (Simply Wall St.)

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Singleton Mark Leonard	SVP & CFO	Mar 21 '25	Option Exercise	0.00	18,625	0	137,442	Mar 21 05:24 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Mar 17 '25	Sale	9.75	1,018	9,926	52,540	Mar 18 05:34 PM
D'Adamio Anthony	SVP & General Counsel	Mar 17 '25	Sale	9.75	2,615	25,496	124,449	Mar 18 05:33 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Mar 14 '25	Option Exercise	0.00	3,456	0	53,558	Mar 14 07:06 PM
D'Adamio Anthony	SVP & General Counsel	Mar 14 '25	Option Exercise	0.00	8,886	0	127,064	Mar 14 07:05 PM
Singleton Mark Leonard	SVP & CFO	Feb 18 '25	Sale	10.19	6,498	66,215	118,817	Feb 20 07:01 PM
D'Adamio Anthony	SVP & General Counsel	Feb 18 '25	Sale	10.19	4,380	44,632	118,178	Feb 20 07:00 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Feb 18 '25	Sale	10.19	1,537	15,662	50,102	Feb 20 07:00 PM
Singleton Mark Leonard	SVP & CFO	Feb 15 '25	Option Exercise	0.00	20,153	0	125,315	Feb 18 06:00 PM
D'Adamio Anthony	SVP & General Counsel	Feb 15 '25	Option Exercise	0.00	12,980	0	122,558	Feb 18 06:00 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Feb 15 '25	Option Exercise	0.00	4,375	0	51,639	Feb 18 05:59 PM
Claypoole Robert E	President and CEO	Jan 13 '25	Sale	9.10	28,786	261,953	64,964	Jan 14 06:59 PM
Claypoole Robert E	Officer	Jan 13 '25	Proposed Sale	9.55	33,000	315,150		Jan 13 09:16 PM
Claypoole Robert E	President and CEO	Jan 10 '25	Option Exercise	0.00	93,750	0	93,750	Jan 13 05:24 PM
Singleton Mark Leonard	SVP & CFO	Dec 23 '24	Sale	10.53	10,733	113,018	105,162	Dec 26 04:55 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Dec 23 '24	Sale	10.53	2,535	26,694	47,264	Dec 26 04:55 PM
D'Adamio Anthony	SVP & General Counsel	Dec 23 '24	Sale	10.53	5,848	61,579	109,578	Dec 26 04:54 PM
Singleton Mark Leonard	Officer	Dec 23 '24	Proposed Sale	11.15	19,000	211,850		Dec 23 05:37 PM
CHURCH KATRINA J	Officer	Dec 23 '24	Proposed Sale	11.15	8,000	89,200		Dec 23 05:35 PM
D'Adamio Anthony	Officer	Dec 23 '24	Proposed Sale	11.15	16,000	178,400		Dec 23 05:34 PM
Singleton Mark Leonard	SVP & CFO	Dec 20 '24	Option Exercise	0.00	31,000	0	115,895	Dec 23 05:28 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Dec 20 '24	Option Exercise	0.00	8,600	0	49,799	Dec 23 05:28 PM
D'Adamio Anthony	SVP & General Counsel	Dec 20 '24	Option Exercise	0.00	19,850	0	115,426	Dec 23 05:27 PM
Bartholdson John A.	Director	Aug 16 '24	Buy	8.55	80,000	683,736	6,913,857	Aug 20 06:16 PM
Bartholdson John A.	Director	Aug 19 '24	Buy	8.55	25,500	217,966	6,939,357	Aug 20 06:16 PM
Singleton Mark Leonard	SVP & CFO	Jun 21 '24	Sale	5.57	9,219	51,350	84,895	Jun 25 04:59 PM
D'Adamio Anthony	SVP & General Counsel	Jun 21 '24	Sale	5.57	5,904	32,885	95,576	Jun 25 04:58 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Jun 21 '24	Sale	5.57	2,559	14,254	41,199	Jun 25 04:58 PM
Singleton Mark Leonard	SVP & CFO	Jun 20 '24	Option Exercise	0.00	31,000	0	94,114	Jun 24 08:46 PM
D'Adamio Anthony	SVP & General Counsel	Jun 20 '24	Option Exercise	0.00	19,850	0	101,480	Jun 24 08:45 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Jun 20 '24	Option Exercise	0.00	8,600	0	43,758	Jun 24 08:45 PM
Singleton Mark Leonard	SVP & CFO	Jun 17 '24	Sale	5.84	13,753	80,318	63,114	Jun 21 04:27 PM
D'Adamio Anthony	SVP & General Counsel	Jun 17 '24	Sale	5.84	11,308	66,039	81,630	Jun 21 04:25 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Jun 17 '24	Sale	5.84	8,759	51,153	35,158	Jun 21 04:24 PM
McMurry-Heath Michelle	Director	Jun 16 '24	Option Exercise	0.00	386	0	48,205	Jun 18 05:44 PM
Ladone Mary Kay	Director	Jun 16 '24	Option Exercise	0.00	1,814	0	52,488	Jun 18 05:43 PM
Beyer Pat	Director	Jun 16 '24	Option Exercise	0.00	965	0	49,943	Jun 18 05:43 PM
Singleton Mark Leonard	SVP & CFO	Jun 15 '24	Option Exercise	0.00	42,202	0	76,867	Jun 18 05:42 PM
D'Adamio Anthony	SVP & General Counsel	Jun 15 '24	Option Exercise	0.00	34,696	0	92,938	Jun 18 05:40 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Jun 15 '24	Option Exercise	0.00	26,875	0	43,917	Jun 18 05:40 PM
SUTTER MARTIN P	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	58,748	Jun 11 08:47 PM
STALNECKER SUSAN M	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	79,464	Jun 11 08:46 PM
NOHRA GUY P	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	100,117	Jun 11 08:46 PM
NEELS GUIDO J	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	58,748	Jun 11 08:45 PM
HAWKINS WILLIAM A	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	231,358	Jun 11 08:45 PM
Ladone Mary Kay	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	50,674	Jun 11 08:44 PM
McMurry-Heath Michelle	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	47,819	Jun 11 08:44 PM
Beyer Pat	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	48,978	Jun 11 08:43 PM
Bartholdson John A.	Director	Jun 07 '24	Option Exercise	0.00	30,400	0	45,552	Jun 11 08:43 PM
Bartholdson John A.	Director	Jun 06 '24	Option Exercise	0.00	7,576	0	15,152	Jun 10 05:40 PM
Singleton Mark Leonard	SVP & CFO	Apr 11 '24	Sale	4.75	4,000	19,000	34,665	Apr 15 06:03 PM
D'Adamio Anthony	SVP & General Counsel	Apr 11 '24	Sale	4.75	3,054	14,506	58,242	Apr 15 06:00 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Apr 11 '24	Sale	4.75	1,325	6,294	17,042	Apr 15 05:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BVS

Bioventus Inc

Upgrade your FINVIZ experience